United Imaging Healthcare (688271.SH) has cumulatively spent 511 million yuan to repurchase 0.57% of its shares.
On June 3, Gelonhui reported that United Imaging Medical (688271.SH) announced its cumulative repurchase of 4,716,821 shares as of May 31, 2024, accounting for 0.57% of the total share capital of the company. The highest purchase price was 140.00 yuan/share, the lowest was 102.20 yuan/share, and the total amount paid was 511,272,168.36 yuan (excluding transaction fees such as stamp duty and commissions). The repurchased shares mentioned above comply with relevant laws and regulations and the company's share repurchase program.
Yimai Sunshine (02522.HK) is expected to go public on June 7 and introduce cornerstones such as Lianying Medical
Gelonghui, May 30, 丨 Yimai Sunshine (02522.HK) announced that the company plans to sell 178.16 million shares globally, 1.782 million shares in Hong Kong, China, and 16.34 million shares; the expected pricing date is June 5 from May 30 to June 4, 2024; the sale price will be HK$14.60-16.80 per share, with 500 shares per lot; CITIC Securities is the sole sponsor; it is expected that the shares will start trading on the main board of the Stock Exchange on June 7, 2024. The company is a leading medical imaging specialist medical group in China.
A Look At The Intrinsic Value Of Shanghai United Imaging Healthcare Co., Ltd. (SHSE:688271)
Key Insights Shanghai United Imaging Healthcare's estimated fair value is CN¥115 based on 2 Stage Free Cash Flow to Equity Shanghai United Imaging Healthcare's CN¥127 share price indicates it is tra
Nomura Adjusts United Imaging Healthcare's Price Target to 139.25 Yuan From 132.88 Yuan, Keeps at Neutral
02:56 AM EDT, 05/24/2024 (MT Newswires) -- Nomura Adjusts United Imaging Healthcare's Price Target to 139.25 Yuan From 132.88 Yuan, Keeps at Neutral
Research Report: CICC: Lianying Healthcare Releases 2024 Incentive Plan to Focus on Achieving Long-term Competitiveness
According to the CICC Research Report, Lianying Healthcare (688271.SH) announced the “2024 Restricted Stock Incentive Plan (Draft)”, believing that the company issued a new incentive plan and aimed at core technicians and middle managers, which is expected to consolidate talent advantages in an increasingly competitive environment, further strengthen business cohesion and output, and guarantee talent support for business development. Looking ahead to the whole year, considering the pace of reform of the domestic medical industry, it is expected that hospital side recruitment activities throughout the year will show a quarterly recovery trend in 2-3 Q24. At the same time, although the medical device industry has been somewhat disrupted in the short term
Lianying Healthcare (688271.SH) appoints Wang Jianbao as the company's financial director
Zhitong Finance App News, Lianying Healthcare (688271.SH) announced that the board of directors of the company recently received the resignation report of TAO CAI, the financial director and chief financial officer, and applied to resign as the company's financial director and chief financial officer due to work reasons. After the resignation, TAO CAI continued to serve as the company's director, board strategy and social responsibility committee member, board secretary and chief investment officer. TAO CAI's resignation report is effective from the date it is delivered to the company's board of directors. Furthermore, the board of directors of the company deliberated and passed the “Proposal on Changing the Company's Financial Officer” on May 21, 2024.
Lianying Healthcare (688271.SH) plans to launch the 2024 Restricted Stock Incentive Plan with an initial grant price of 88 yuan/share
Lianying Healthcare (688271.SH) disclosed the 2024 Restricted Stock Incentive Plan (draft). The incentive plan...
Lianying Medical (688271.SH): The transfer price in this inquiry is 116.1 yuan/share
On May 20, Ge Longhui Medical (688271.SH) announced that after requesting quotations from institutional investors, the initial determined transfer price was 116.10 yuan/share, which is 91.47% of the closing price of 126.93 yuan/share on Lianying Medical shareholders' inquiry and transfer pricing date (that is, May 20, 2024). The number of institutional investors participating in this inquiry and transfer quotation was 15, covering fund management companies, insurance companies, qualified overseas institutional investors, securities companies, private equity fund management and other professional institutional investors. The total valid subscription amount for institutional investors participating in this inquiry and transfer quotation is about 1
Shareholders of Lianying Medical (688271.SH), Zhongke Daofu and Beiyuan Investment plan to transfer 1.09% of the company's shares in an inquiry
Lianying Medical (688271.SH) disclosed the shareholder inquiry and transfer plan. The shareholder to participate in this inquiry and transfer is Zhongke...
Lianying Healthcare (688271.SH): 0.57% of shares have been repurchased cumulatively
Gelonghui, May 6, 丨 Lianying Medical (688271.SH) announced that as of April 30, 2024, the company had repurchased 4,716,821 shares, accounting for 0.57% of the company's total share capital. The highest purchase price was 140.00 yuan/share, the lowest price was 102.20 yuan/share, and the total amount paid was 511,272,168.36 yuan (excluding transaction fees such as stamp duty and transaction commissions).
Shanghai United Imaging Healthcare's (SHSE:688271) Earnings Might Not Be As Promising As They Seem
Following the release of a positive earnings report recently, Shanghai United Imaging Healthcare Co., Ltd.'s (SHSE:688271) stock performed well. Investors should be cautious however, as there some ca
Nomura Adjusts Shanghai United Imaging Healthcare's Price Target to 132.88 Yuan From 134.26 Yuan, Keeps at Neutral
03:43 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Shanghai United Imaging Healthcare's Price Target to 132.88 Yuan From 134.26 Yuan, Keeps at Neutral
Returns At Shanghai United Imaging Healthcare (SHSE:688271) Are On The Way Up
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a business will show two trends; firstly a growing return on capital employed (ROC
Research Report Nuggets丨CICC: Lianying Healthcare's performance is in line with expectations and maintains “outperforming the industry” rating
According to the CICC research report, Lianying Healthcare (688271.SH)'s 2023 and 1Q24 results are in line with our expectations. Net profit to mother in '23 was $1,974 million (+19.21% YoY), and net profit to mother was $363 million (+10.20% YoY). High-end products drive MR production lines. PET/CT, PET/MR and XR products all rank first in the industry according to the new domestic market value in 2023, and CT, MR and RT products also rank at the top of the industry. Looking ahead to the whole year, considering the pace of reform of the domestic medical industry, the whole year is expected
Lianying Healthcare (688271.SH) announced first-quarter results, net profit of 363 million yuan, up 10.2% year on year
Zhitong Finance App News, Lianying Healthcare (688271.SH) released its report for the first quarter of 2024. The company's revenue was 2.35 billion yuan, up 6.22% year on year; net profit attributable to shareholders of listed companies was 363 million yuan, up 10.20% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 300 million yuan, up 8.52% year on year; basic earnings per share were 0.44 yuan/share.
United Imaging Healthcare Releases 2023 Annual Report, With Revenue Growth of 23.52%
Along with the publication of its 2023 annual report and the Q1 2024 report, United Imaging Healthcare released its ESG report. SHANGHAI, April 27, 2024 /PRNewswire/ -- United Imaging Healthcare (SSE:
Lianying Medical (688271.SH) has repurchased a total of 0.57% of its shares at a cost of 511 million yuan
Lianying Medical (688271.SH) announced that as of March 31, 2024, the company had repurchased a total of 47 shares...
Lianying Healthcare (688271.SH): The employee shareholding platform plans to reduce the company's shares by no more than 1%
Lianying Medical (688271.SH) issued an announcement. The company's employee shareholding platforms (Ningbo Film Festival, Ningbo Film Power, Ningbo...
Guolian Securities: Medical AI empowers the healthcare industry chain and focuses on companies with leading technology layout and strong commercialization capabilities
Healthcare is one of the important fields of large-scale application of artificial intelligence technology (AI).
Guojin Securities: Medical equipment updates are expected to accelerate demand for high-end innovative medical equipment is expected to be released
It is recommended to focus on segments such as surgical robotics, endoscopes, ultrasound, and ICU equipment.
No Data